Polyclonal antibody stimulator - Cancer Advances

Drug Profile

Polyclonal antibody stimulator - Cancer Advances

Alternative Names: Anti-gastrin 17 immunogen; G17DT; Gastrimmune; Insegia; PAS

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aphton Corporation
  • Developer Cancer Advances
  • Class Antiulcers; Cancer vaccines; Peptide hormones
  • Mechanism of Action Gastrin 17 inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • Phase II Colorectal cancer; Gastro-oesophageal reflux

Most Recent Events

  • 24 Jan 2018 Polyclonal Antibody Stimulator (PAS) is still in phase III trials for Pancreatic cancer in USA (Cancer Advances pipeline, January 2018)
  • 11 May 2015 The product is in phase-III development for Gastric cancer and phase-II for Gastro-oesophageal reflux in USA, and phase-II for Colorectal cancer in USA and Europe
  • 03 Feb 2011 Polyclonal antibody stimulator - Cancer Advances is still available for licensing as of 01 Jan 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top